Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
CytoMed Therapeutics Limited (GDTC) had Stock-Based Compensation of $0.35M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$3.21M |
|
$2.73M |
|
$3.36M |
|
$6.57M |
|
$0.55M |
|
$0.34M |
|
$0.34M |
|
$0.89M |
|
$5.68M |
|
$5.62M |
|
$5.68M |
|
11.54M |
|
| Cash Flow Statement Financials | |
$-1.26M |
|
$-0.02M |
|
$-0.03M |
|
$3.69M |
|
$2.24M |
|
$-1.45M |
|
|
Stock-Based Compensation |
$0.35M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|